- Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma2022 | First Faculty of Medicine
- ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma2021 | Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression(aEuro)2016 | Publication without faculty affiliation
- Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial2018 | Second Faculty of Medicine
- A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis2014 | First Faculty of Medicine
- Gencitabine plus Cisplatin versus Gemcitabine plus carboplatin in Stage IIIb and IV Non. Small Cell Lung Cancer: A Phase III Randomized TrialPublication without faculty affiliation
- Phase III Trial Comparing Vinflunine With Docetaxel in Second-Line Advanced Non-Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy2010 | Third Faculty of Medicine
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival2010 | Faculty of Medicine in Hradec Králové
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.2011 | First Faculty of Medicine
- Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study2021 | Second Faculty of Medicine
- Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial2009 | First Faculty of Medicine
- Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial2007 | Faculty of Medicine in Pilsen
- Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial2007 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals2013 | Faculty of Medicine in Pilsen
- Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial2023 | First Faculty of Medicine
- EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer2008 | Second Faculty of Medicine
- AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma2019 | First Faculty of Medicine
- Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study2023 | Publication without faculty affiliation
- Sklopísek Střeleč, assessment of stability inside the hopper, Phase III: Numerical Analysis, plus dumpPublication without faculty affiliation
- Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial2010 | First Faculty of Medicine
- A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)2017 | Faculty of Medicine in Hradec Králové
- Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial2003 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma2019 | First Faculty of Medicine
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL2009 | Third Faculty of Medicine
- The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial2019 | Faculty of Medicine in Pilsen
- Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes2021 | First Faculty of Medicine
- The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma2022 | Faculty of Medicine in Hradec Králové
- Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study2017 | Second Faculty of Medicine
- Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants2021 | Faculty of Medicine in Hradec Králové
- A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer2012 | Third Faculty of Medicine